Ulcerative colitis-associated colorectal cancer

被引:202
作者
Yashiro, Masakazu [1 ,2 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Oncol Inst Geriatr & Med Sci, Osaka 5458585, Japan
关键词
Ulcerative colitis-associated colorectal cancer; Risk factor; Dysplasia; Surveillance colonoscopy; Chemoprevention; INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; PRIMARY SCLEROSING CHOLANGITIS; LOW-GRADE DYSPLASIA; PRACTICE PARAMETERS COMMITTEE; EVIDENCE-BASED CONSENSUS; RISK-FACTORS; FOLLOW-UP; COLONOSCOPIC SURVEILLANCE; CROHNS-DISEASE;
D O I
10.3748/wjg.v20.i44.16389
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The association between ulcerative colitis (UC) and colorectal cancer (CRC) has been acknowledged. One of the most serious and life threatening consequences of UC is the development of CRC (UC-CRC). UC-CRC patients are younger, more frequently have multiple cancerous lesions, and histologically show mucinous or signet ring cell carcinomas. The risk of CRC begins to increase 8 or 10 years after the diagnosis of UC. Risk factors for CRC with UC patients include young age at diagnosis, longer duration, greater anatomical extent of colonic involvement, the degree of inflammation, family history of CRC, and presence of primary sclerosing cholangitis. CRC on the ground of UC develop from non-dysplastic mucosa to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of UC-CRC. 5-aminosalicylates might represent a favorable therapeutic option for chemoprevention of CRC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:16389 / 16397
页数:9
相关论文
共 107 条
[1]   Family history as a risk factor for colorectal cancer in inflammatory bowel disease [J].
Askling, J ;
Dickman, PW ;
Karlén, P ;
Broström, O ;
Lapidus, A ;
Löfberg, R ;
Ekbom, A .
GASTROENTEROLOGY, 2001, 120 (06) :1356-1362
[2]   Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease:: a population-based cohort study [J].
Askling, J ;
Dickman, PW ;
Karlén, P ;
Broström, O ;
Lapidus, A ;
Löfberg, R ;
Ekbom, A .
LANCET, 2001, 357 (9252) :262-266
[3]   Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis [J].
Averboukh, F. ;
Ziv, Y. ;
Kariv, Y. ;
Zmora, O. ;
Dotan, I. ;
Klausner, J. M. ;
Rabau, M. ;
Tulchinsky, H. .
COLORECTAL DISEASE, 2011, 13 (11) :1230-1235
[4]  
Bansal P, 1996, AM J GASTROENTEROL, V91, P44
[5]   Low grade dysplasia in extensive, long-standing inflammatory bowel disease - A follow-up study [J].
Befrits, R ;
Ljung, T ;
Jaramillo, E ;
Rubio, C .
DISEASES OF THE COLON & RECTUM, 2002, 45 (05) :615-620
[6]   5-Aminosalicylate Is Not Chemoprophylactic for Colorectal Cancer in IBD: A Population Based Study [J].
Bernstein, Charles N. ;
Nugent, Zoann ;
Blanchard, James F. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) :731-736
[7]  
BERNSTEIN CN, 1994, LANCET, V343, P71
[8]  
Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
[9]  
2-Z
[10]   European evidence-based Consensus on the management of ulcerative colitis: Special situations (Publication with Expression of Concern) [J].
Biancone, Livia ;
Michetti, Pierre ;
Travis, Simon ;
Escher, Johanna C. ;
Moser, Gabriele ;
Forbes, Alastair ;
Hoffmann, Joerg C. ;
Dignass, Axel ;
Gionchetti, Paolo ;
Jantschek, Guenter ;
Kiesslich, Ralf ;
Kolacek, Sanja ;
Mitchell, Rod ;
Panes, Julian ;
Soderholm, Johan ;
Vucelic, Boris ;
Stange, Eduard .
JOURNAL OF CROHNS & COLITIS, 2008, 2 (01) :63-92